Stephen Dale, M.D.

Stephen Dale, M.D.

Former Chief Medical OfficeratKura Oncology· In proxies 2021–2024

Pay in FY2024Kura Oncology stock -39.4% the same year

Stephen Dale, M.D. was paid $2.5M in FY2024 (Dec). Kura Oncology stock fell 39.4% that year.

Pay$100 in the stock at the end of FY20 → $23
Pay is from the Summary Compensation Table of each Kura Oncology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Kura OncologyPublic company · 5 yr
    • Former Chief Medical Officer2021 – Present · 5 yrStock in role -70%

Roles come from the proxy statements of each company.

Activity

Two people shown as one, or a wrong number?